Literature DB >> 29863908

Excipients in parenteral formulations: selection considerations and effective utilization with small molecules and biologics.

Bindhu Madhavi Rayaprolu1, Jonathan J Strawser1, Gopal Anyarambhatla1.   

Abstract

Excipients form a major component of pharmaceutical formulations and are classified as any ingredient other than the active ingredient which is included within the product formulation to improve drug product performance. Functional uses of excipients include improving solubility and stability, safety and efficacy, as bulking agents in lyophilized formulations, tonicity agents, and aiding in controlled or prolonged drug delivery. Parenteral formulations are sterile, pyrogen-free; free of particulate matter and by-pass the body's natural defense mechanisms. Excipients may demonstrate a synergistic effect when combined with an active ingredient but may also lead to unwanted reactions with the drugs and packaging components. Ideal excipients are required to be considered safe, inert and multifunctional. Contrary to the past, safety of excipients needs to be well established in order for their use in the pharmaceutical formulations. Therefore, careful consideration should be given while selecting an excipient. This review article provides an overview of the excipients used exclusively in small molecule and biological parenteral products including solutions, suspensions, and lyophilized formulations, information on the possible drug-excipient and drug-packaging interactions and the regulatory requirements for the use of pharmaceutical excipients. The readers will be able to have a comprehensive understanding of the excipients used in parenteral formulations.

Keywords:  Parenterals; drug-excipient interactions; excipients; lyophilized pharmaceuticals; regulatory consideration of excipients

Mesh:

Substances:

Year:  2018        PMID: 29863908     DOI: 10.1080/03639045.2018.1483392

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  9 in total

1.  Case Study in the Design of a Surrogate Solution for Use in Biopharmaceutical Drug Product Process Development.

Authors:  Kevin Boksa; Peter Walsh; Ambarish Shah
Journal:  AAPS PharmSciTech       Date:  2021-01-06       Impact factor: 3.246

Review 2.  Engineering biopharmaceutical formulations to improve diabetes management.

Authors:  Caitlin L Maikawa; Andrea I d'Aquino; Rayhan A Lal; Bruce A Buckingham; Eric A Appel
Journal:  Sci Transl Med       Date:  2021-01-27       Impact factor: 17.956

3.  Osmolality of Excipients for Parenteral Formulation Measured by Freezing Point Depression and Vapor Pressure - A Comparative Analysis.

Authors:  Mariana Hugo Silva; Sarah P Hudson; Lidia Tajber; Matthieu Garin; Wenyu Dong; Tatsiana Khamiakova; René Holm
Journal:  Pharm Res       Date:  2022-04-22       Impact factor: 4.200

4.  Stable Monomeric Insulin Formulations Enabled by Supramolecular PEGylation of Insulin Analogues.

Authors:  Caitlin L Maikawa; Anton A A Smith; Lei Zou; Catherine M Meis; Joseph L Mann; Matthew J Webber; Eric A Appel
Journal:  Adv Ther (Weinh)       Date:  2019-12-17

Review 5.  Formulation strategies in immunotherapeutic pharmaceutical products.

Authors:  Yajie Zhang; Robert O Williams Iii; Haley Oana Tucker
Journal:  World J Clin Oncol       Date:  2020-05-24

6.  Excipient Innovation Through Precompetitive Research.

Authors:  Yihua Bruce Yu; Marc B Taraban; Katharine T Briggs; Robert G Brinson; John P Marino
Journal:  Pharm Res       Date:  2021-12-20       Impact factor: 4.580

7.  Ciprofloxacin-Loaded Zein/Hyaluronic Acid Nanoparticles for Ocular Mucosa Delivery.

Authors:  Telma A Jacinto; Breno Oliveira; Sónia P Miguel; Maximiano P Ribeiro; Paula Coutinho
Journal:  Pharmaceutics       Date:  2022-07-27       Impact factor: 6.525

Review 8.  An expanding horizon of complex injectable products: development and regulatory considerations.

Authors:  Kanan Panchal; Sumeet Katke; Sanat Kumar Dash; Ankit Gaur; Aishwarya Shinde; Nithun Saha; Neelesh Kumar Mehra; Akash Chaurasiya
Journal:  Drug Deliv Transl Res       Date:  2022-08-14       Impact factor: 5.671

9.  Degradation kinetics of artesunate for the development of an ex-tempore intravenous injection.

Authors:  Fanta Gashe; Evelien Wynendaele; Bart De Spiegeleer; Sultan Suleman
Journal:  Malar J       Date:  2022-09-06       Impact factor: 3.469

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.